Cytokines in Sjogren's syndrome: potential therapeutic targets. - Wikidata - awgldk - TriplyDB

Cytokines in Sjogren's syndrome: potential therapeutic targets.

Cytokines in Sjogren's syndrome: potential therapeutic targets.

http://www.wikidata.org/entity/Q34601660

about

Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.Effect of mesenchymal stem cells on Sjögren-like mice and the microRNA expression profiles of splenic CD4+ T cells Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes Genetics and genomics of Sjögren's syndrome: research provides clues to pathogenesis and novel therapies.Innate immune signaling induces interleukin-7 production from salivary gland cells and accelerates the development of primary Sjögren's syndrome in a mouse model Genetic and pharmacologic inhibition of the Ca2+ influx channel TRPC3 protects secretory epithelia from Ca2+-dependent toxicity.Upregulation of NLRP3 Inflammasome in the Tears and Ocular Surface of Dry Eye Patients.Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren's syndrome TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice.Frankincense and myrrh suppress inflammation via regulation of the metabolic profiling and the MAPK signaling pathway Significance of Interleukin-6/STAT Pathway for the Gene Expression of REG Iα, a New Autoantigen in Sjögren's Syndrome Patients, in Salivary Duct Epithelial Cells.Serum interleukin-17 & nitric oxide levels in patients with primary Sjögren's syndrome.Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditions T Cell-Associated Cytokines in the Pathogenesis of Sjögren's Syndrome Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.Interleukin-7 enhances the Th1 response to promote the development of Sjögren's syndrome-like autoimmune exocrinopathy in mice Endogenous programmed death ligand-1 restrains the development and onset of Sjӧgren's syndrome in non-obese diabetic mice.Smad4 in T cells plays a protective role in the development of autoimmune Sjögren's syndrome in the nonobese diabetic mouse.Pathogenic role of endogenous TNF-α in the development of Sjögren's-like sialadenitis and secretory dysfunction in non-obese diabetic mice.Biological therapies in primary Sjögren's syndrome.Biologics in oral medicine: Sjogren syndrome.Biologic treatment in Sjögren's syndrome.Evaluation of chemical constituents and important mechanism of pharmacological biology in dendrobium plants.Polysaccharides of Dendrobium officinale inhibit TNF-α-induced apoptosis in A-253 cell line.Use of biologic agents in ocular manifestations of rheumatic disease.Effect of Systemic Infliximab Therapy in Patients with Sjögren's Syndrome.P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy.Interleukin-6/STAT pathway is responsible for the induction of gene expression of REG Iα, a new auto-antigen in Sjögren׳s syndrome patients, in salivary duct epithelial cells.Correlation of interleukin-33 with Th cytokines and clinical severity of dry eye disease.Cholinergic anti-inflammatory pathway in the non-obese diabetic mouse model.Sjögren-Like Lacrimal Keratoconjunctivitis in Germ-Free Mice.Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.Rotavirus intestinal infection induces an oral mucosa cytokine response.Co-culture system of human salivary gland epithelial cells and immune cells from primary Sjögren's syndrome patients: an in vitro approach to study the effects of Rituximab on the activation of the Raf-1/ERK1/2 pathway.Elevated level of circulating CD4+Helios+FoxP3+ cells in primary Sjogren's syndrome patients.IL-17A and IL-17F polymorphisms in rheumatoid arthritis and Sjögren’s syndrome

P2860

Q33667694-E3D1262C-8F25-46C1-8660-34C02E78E372 Q33744508-491F0272-A160-4F65-9FB0-2CCD92E94B90 Q34083843-C0D93DFE-0316-4C03-B118-46EBA986DF77 Q34984739-E45D313A-A39B-49CC-BBF3-394A00ACD2CD Q35023259-46247BD5-78DB-4EFD-B2D4-0BA63361F6E1 Q35028058-59309DCB-DE99-4357-BB8E-3116844A269D Q35592392-8816B8E6-B124-4F93-9F92-B15BC972B951 Q35676007-D7367C75-021C-4016-B890-65721C06A71D Q35857131-7DAD82C5-3D34-48F6-A389-FB05258410F5 Q36017886-27DB9FA1-B671-49F7-8DA7-6C9FF42B5B63 Q36060629-9E03029D-BEFB-4D6A-9E33-F963849D0E2F Q36064302-5D6F670E-04A8-4FB8-AD76-B523DE9BB2CE Q36161896-9FCCC3E3-09FE-4D43-A345-28CDCAA360A7 Q36957148-B3E32F36-9A0A-4848-9C95-53E9A9558BBB Q36989837-534607CD-0FBA-47AF-9398-E4EDBFBC635C Q37060371-79A50C3C-99DE-43C3-8952-71D23E762181 Q37501812-76AE8716-FAE4-440F-A183-901B0A337F43 Q37696996-BA63B48C-A023-491D-8352-1B26453F1729 Q37733323-B1765B51-C820-4F27-A02E-D25020D0F812 Q37860347-28DCDA18-39B7-4764-8177-AA57C8D0D1F2 Q38002156-F819F39E-5255-4336-BAC8-A763EF092C2B Q38262453-F51C369D-47EB-4571-A763-2B96864FF305 Q38461770-F666D6D5-F250-4B75-95E2-A96A129E1531 Q39221016-76CA1431-F4AB-487C-8649-25395E0F7D20 Q40008319-EBB97A6E-F266-4BC5-AAED-1784B9BA1479 Q41592241-8EA643B6-55AF-4736-839D-1A6F682751B4 Q46322679-1A6FB26F-567A-447E-93E0-A984963517C5 Q46974371-E8663F31-9643-4652-ABDA-7FF5AE260892 Q47250165-3F50C9B5-5E72-43E5-AF38-D4473083BD78 Q49131251-D204AFDF-6AF5-43D7-8E12-FAD779798244 Q50041932-9DBC8473-DA0F-4850-AC8D-F4DB186943A9 Q53542274-763C8245-B73F-4995-A8D8-4549D4DD616A Q54241218-BE75556C-BE26-4830-9319-2FFA179498C2 Q54310740-47C718D9-6AC5-40FE-83B5-B94229543CA6 Q54400978-C3AB0239-CDEA-4474-B2C3-CB3D365DD706 Q56786588-ED563D8B-6565-4479-BB9A-4C8A02C07AD7

P2860

Cytokines in Sjogren's syndrome: potential therapeutic targets.

http://www.wikidata.org/entity/Q34601660

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cytokines in Sjogren's syndrome: potential therapeutic targets.

@ast

Cytokines in Sjogren's syndrome: potential therapeutic targets.

@en

Cytokines in Sjogren's syndrome: potential therapeutic targets.

@nl

type

label

Cytokines in Sjogren's syndrome: potential therapeutic targets.

@ast

Cytokines in Sjogren's syndrome: potential therapeutic targets.

@en

Cytokines in Sjogren's syndrome: potential therapeutic targets.

@nl

prefLabel

Cytokines in Sjogren's syndrome: potential therapeutic targets.

@ast

Cytokines in Sjogren's syndrome: potential therapeutic targets.

@en

Cytokines in Sjogren's syndrome: potential therapeutic targets.

@nl

P1433

Q34601660-C990966D-DDD6-4114-A528-F8F2D3327171

P1476

Q34601660-B0F1145C-8374-4391-9620-258EB38E1CDC

P2093

Q34601660-1A50D6F5-A63D-4AC9-93B2-E380D052B266

Q34601660-50B73F8E-FFAE-416E-A061-BB64491D268A

Q34601660-AB37D652-CE4D-487F-B537-05B2A442CC81

P2860

Q34601660-08FE3CDF-37A9-4DF1-A0C5-B2BFCABA134E

Q34601660-17BCC7D8-68AA-4E2B-B5F3-C1D11EF72DEF

Q34601660-42613C37-70D4-4766-A7AA-EBBA19ED8AF9

Q34601660-54D27D8A-785C-4BCA-B16E-9D6BBEB96436

Q34601660-553A5118-06A0-4D94-A280-E5C7D290D9F6

Q34601660-59856BD0-A1EE-41ED-884E-AF9D43750B70

Q34601660-5A2691A0-666F-4A70-B4B1-D355CAD583BE

Q34601660-65B44FC6-983E-4F1B-AC15-F7DEAFED71C7

Q34601660-6AEFD2F2-E564-479C-910A-2E1316A486EF

Q34601660-710DD3DA-5206-45BE-B4B5-509F9DCD7D5B

P304

Q34601660-E20623A0-E5EA-42E4-83F4-26033E74F6D0

P31

Q34601660-F0438EA2-F2B3-4999-97F1-07E9917FBC66

P356

Q34601660-89BDDCFF-8E0A-404B-A0DD-1FECDB530875

P407

Q34601660-3ED19F2A-95B1-4139-AF48-AE8B5156E2A6

P433

Q34601660-24843309-61E0-4D9E-9B2E-B8CCC43E1DA4

P478

Q34601660-83C1CBA1-F48D-4BB8-93FD-96265B7DA87E

P577

Q34601660-BF41E489-E612-4495-840F-A43DE387705D

P5875

Q34601660-55F49707-1578-40F7-9308-A725BFD7F4ED

P698

Q34601660-F8C0853F-707C-4D70-BB57-411AD196BD25

P932

Q34601660-BAF8BAB1-1B36-4665-898B-1DD27F162A78

P356

ARD.2009.115378

P1433

Annals of the Rheumatic Diseases

P1476

Cytokines in Sjogren's syndrome: potential therapeutic targets.

@en

P2093

Gabor G Illei

http://www.w3.org/2001/XMLSchema#string

Nienke Roescher

http://www.w3.org/2001/XMLSchema#string

Paul P Tak

http://www.w3.org/2001/XMLSchema#string

P2860

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus

The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome

Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.

Peripheral blood gene expression profiling in Sjögren's syndrome

Systemic effects of interferons after oral administration in animals and humans.

ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.

Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis

P304

945-948

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2009.115378

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43247248

http://www.w3.org/2001/XMLSchema#string

P698

20410069

http://www.w3.org/2001/XMLSchema#string

P932

3044243

http://www.w3.org/2001/XMLSchema#string